Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bacteriophage cocktail
- Development stage
- Unknown
- Lead developer
- Chinese PLA General Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Inhalation
01
Overview
This bacteriophage cocktail is an experimental therapeutic developed by the Chinese PLA General Hospital for the treatment of ventilator-associated pneumonia (VAP) caused by multidrug-resistant (MDR) Gram-negative bacteria. The cocktail is composed of multiple lytic bacteriophages specifically selected to target and lyse pathogenic bacteria such as *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Klebsiella pneumoniae*. Administered via nebulization, the therapy delivers the phages directly to the site of infection in the lungs, where they replicate within and destroy the target bacterial cells while sparing the host's commensal microbiota. This approach is being evaluated as a potential alternative or adjunct to conventional antibiotics in patients with severe respiratory infections caused by highly resistant bacterial strains.
- Other names
- Phage cocktailInhaled bacteriophage cocktailBacteriophage cocktail therapy
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)OmpC (Outer membrane porin C)LPS (Lipopolysaccharide)
Beyond the preview
Go deeper on Bacteriophage cocktail.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bacteriophage cocktail.